Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Total Liabilities (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Total Liabilities for 10 consecutive years, with $53.2 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 17.43% to $53.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.2 million through Dec 2025, down 17.43% year-over-year, with the annual reading at $53.2 million for FY2025, 17.43% down from the prior year.
  • Total Liabilities hit $53.2 million in Q4 2025 for Rocket Pharmaceuticals, down from $54.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $96.5 million in Q1 2021 to a low of $42.3 million in Q4 2021.
  • Historically, Total Liabilities has averaged $57.8 million across 5 years, with a median of $57.8 million in 2023.
  • Biggest YoY gain for Total Liabilities was 46.87% in 2022; the steepest drop was 55.92% in 2022.
  • Year by year, Total Liabilities stood at $42.3 million in 2021, then surged by 46.87% to $62.1 million in 2022, then grew by 18.75% to $73.8 million in 2023, then decreased by 12.61% to $64.5 million in 2024, then fell by 17.43% to $53.2 million in 2025.
  • Business Quant data shows Total Liabilities for RCKT at $53.2 million in Q4 2025, $54.4 million in Q3 2025, and $66.8 million in Q2 2025.